Increased Osteoprotegerin Level is Associated with Impaired Cardiovagal Modulation in Type-2 Diabetic Patients Treated with Oral Antidiabetic Drugs

Overview

Journal BMC Cardiovasc Disord

Publisher Biomed Central

Specialty Cardiology & Vascular Diseases

Date 2020 Oct 21

PMID 33081726

Citations 3

Authors

M R Jasmine

Nivedita Nanda

Jayaprakash Sahoo

S Velkumary

G K Pal

Affiliations

Soon will be listed here.

Abstract

Background: An increased osteoprotegerin (OPG) level has been reported in both type-2 diabetes mellitus (T2DM) and cardiovascular diease (CVD) that are linked to sympathovagal imbalance (SVI). We explored the link of osteoprotegerin with cardiovagal modulation in T2DM.

Methods: We assessed fasting serum OPG, high-sensitive C-reactive protein (hsCRP), glucose, insulin and lipid profile in patients having T2DM receiving oral antidiabetic drugs (OAD) (n = 42) compared with age, gender and body composition-matched healthy participants without diabetes (n = 42). Rate pressure product (RPP), spectral indices of heart rate variability (HRV) and body composition were recorded in both the groups. Association of HOMA-IR and OPG with various parameters were assessed.

Results: Osteoprotegerin, HOMA-IR, hsCRP, coronary lipid risk factor were significantly increased, markers of cardiovagal modulation (TP, SDNN, RMSSD) were considerably decreased, ratio of low-frequency to high-frequency (LH-HF ratio), the indicator of SVI, and RPP, the marker of myocardial work stress were significantly higher in patients with diabetes, suggesting an overall elevated CVD risks in them. HOMA-IR was correlated with RMSSD, lipid risk factors and OPG. Rise in OPG was correlated with decreased cardiovagal modulation in patients with diabetes. There was significant contribution of OPG in decreasing TP, suggesting impaired cardiovagal modulation.

Conclusion: T2DM patients receiving OAD had higher cardiometabolic risks compared to age, gender and body composition-matched healthy individuals. Increased level of OPG is linked to decreased cardiovagal modulation in T2DM patients.

Citing Articles

Association of rs2073618 polymorphism and osteoprotegerin levels with hypertension and cardiovascular risks in patients with type 2 diabetes mellitus.

Sailaja A, Nanda N, Suryanarayana B, Pal G Sci Rep. 2023; 13(1):17451.

PMID: 37838749 PMC: 10576806. DOI: 10.1038/s41598-023-44554-0.

Inflammation and decreased cardiovagal modulation are linked to stress and depression at 36th week of pregnancy in gestational diabetes mellitus.

Renugasundari M, Pal G, Chaturvedula L, Nanda N, Harichandrakumar K, Durgadevi T Sci Rep. 2023; 13(1):10348.

PMID: 37365247 PMC: 10293198. DOI: 10.1038/s41598-023-37387-4.

Hypertension attenuates the link of osteoprotegerin to reduced baroreflex sensitivity in type 2 diabetes mellitus patients on oral antidiabetic and antihypertensive therapy - a cross sectional study.

Sailaja A, Nanda N, Suryanarayana B, Pal G BMC Endocr Disord. 2022; 22(1):226.

PMID: 36085061 PMC: 9463832. DOI: 10.1186/s12902-022-01137-w.

References

Tsuji H, Larson M, Venditti Jr F, Manders E, Evans J, Feldman C . Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation. 1996; 94(11):2850-5. DOI: 10.1161/01.cir.94.11.2850. View

Sucharita S, Bantwal G, Idiculla J, Ayyar V, Vaz M . Autonomic nervous system function in type 2 diabetes using conventional clinical autonomic tests, heart rate and blood pressure variability measures. Indian J Endocrinol Metab. 2011; 15(3):198-203. PMC: 3156541. DOI: 10.4103/2230-8210.83406. View

. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 1996; 93(5):1043-65. View

Bernardi S, Fabris B, Thomas M, Toffoli B, Tikellis C, Candido R . Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes. Mol Cell Endocrinol. 2014; 394(1-2):13-20. DOI: 10.1016/j.mce.2014.06.004. View

Candido R, Toffoli B, Corallini F, Bernardi S, Zella D, Voltan R . Human full-length osteoprotegerin induces the proliferation of rodent vascular smooth muscle cells both in vitro and in vivo. J Vasc Res. 2009; 47(3):252-61. DOI: 10.1159/000257339. View

Dimitrow P, Jawien M, Gackowski A . The influence of statins on levels of calcification biomarkers in patients with aortic sclerosis or mild aortic stenosis. J Heart Valve Dis. 2011; 20(1):18-22. View

Shaffer F, Ginsberg J . An Overview of Heart Rate Variability Metrics and Norms. Front Public Health. 2017; 5:258. PMC: 5624990. DOI: 10.3389/fpubh.2017.00258. View

. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016; 387(10027):1513-1530. PMC: 5081106. DOI: 10.1016/S0140-6736(16)00618-8. View

Pal G, Ganesh V, Karthik S, Nanda N, Pal P . The effects of short-term relaxation therapy on indices of heart rate variability and blood pressure in young adults. Am J Health Promot. 2013; 29(1):23-8. DOI: 10.4278/ajhp.130131-QUAN-52. View

10.

Auroprajna P, Naik B, Sahoo J, Keerthi G, Pavanya M, Pal G . Association of Sympathovagal Imbalance With Cognitive Impairment in Type 2 Diabetes in Adults. Can J Diabetes. 2017; 42(1):44-50. DOI: 10.1016/j.jcjd.2017.01.008. View

11.

Terekeci H, Senol M, Top C, Sahan B, Celik S, Sayan O . Plasma osteoprotegerin concentrations in type 2 diabetic patients and its association with neuropathy. Exp Clin Endocrinol Diabetes. 2008; 117(3):119-23. DOI: 10.1055/s-0028-1085425. View

12.

Suliburska J, Bogdanski P, Gajewska E, Kalmus G, Sobieska M, Samborski W . The association of insulin resistance with serum osteoprotegerin in obese adolescents. J Physiol Biochem. 2013; 69(4):847-53. DOI: 10.1007/s13105-013-0261-8. View

13.

Chen W, Rijzewijk L, van der Meer R, Heymans M, van Duinkerken E, Lubberink M . Association of plasma osteoprotegerin and adiponectin with arterial function, cardiac function and metabolism in asymptomatic type 2 diabetic men. Cardiovasc Diabetol. 2011; 10:67. PMC: 3157422. DOI: 10.1186/1475-2840-10-67. View

14.

Matheus A, Tannus L, Cobas R, Palma C, Negrato C, Gomes M . Impact of diabetes on cardiovascular disease: an update. Int J Hypertens. 2013; 2013:653789. PMC: 3603160. DOI: 10.1155/2013/653789. View

15.

Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S . Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care. 2009; 32 Suppl 2:S314-21. PMC: 2811443. DOI: 10.2337/dc09-S330. View

16.

Knudsen S, Foss C, Poulsen P, Andersen N, Mogensen C, Rasmussen L . Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol. 2003; 149(1):39-42. DOI: 10.1530/eje.0.1490039. View

17.

Simonet W, Lacey D, Dunstan C, Kelley M, Chang M, Luthy R . Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89(2):309-19. DOI: 10.1016/s0092-8674(00)80209-3. View

18.

Keerthi G, Pal P, Pal G, Sahoo J, Sridhar M, Balachander J . Attenuated baroreflex sensitivity in normotensive prediabetes and diabetes in Indian adults. Endocr Res. 2015; 41(2):89-97. DOI: 10.3109/07435800.2015.1076454. View

19.

Saely C, Eber B, Pfeiffer K, Drexel H . Low serum LDL cholesterol in patients with type 2 diabetes: an analysis on two different patient populations. Int J Cardiol. 2009; 144(3):394-8. DOI: 10.1016/j.ijcard.2009.04.048. View

20.

Nanda N, Bobby Z, Hamide A, Koner B, Sridhar M . Association between oxidative stress and coronary lipid risk factors in hypothyroid women is independent of body mass index. Metabolism. 2007; 56(10):1350-5. DOI: 10.1016/j.metabol.2007.05.015. View